HIMS Stock Price Today (April 2026) — Hims & Hers Health, Inc. Analysis & Key Metrics 2026-04-15
Hims & Hers Health, Inc. (HIMS) is trading at $26.99, up 26.36% today (as of April 2026). The stock continues to show early recovery signs above the short-term average, attracting attention from investors looking for Healthcare growth opportunities.
- According to consensus analyst estimates, the 1-year price target is $24.15 (-10.5% upside).
- Volatility remains elevated (66.24% annualized), implying wide price swings for short-term traders.
- The fundamental picture, based on the latest financial filings, is nuanced: solid revenue growth (28.40% YoY) alongside significant competitive pressures.
HIMS Stock Analysis: Key Metrics & Valuation (April 2026)
Concise, actionable data for investors
Hims & Hers Health, Inc. - Historical Price & Volume
Market Cap
Enterprise Value: $4.91B
P/E Ratio
Forward P/E: 11.58
Revenue Growth
Year over Year
Analyst Target
+-10.5% upside potential
Key Investor Questions About HIMS
What investors need to know before buying
Based on current market data, HIMS presents a neutral technical setup with caution warranted fundamentals.
- Technicals say: Neutral (RSI 58.33)
- Fundamentals say: Caution warranted (high leverage concerns)
HIMS's growth trajectory depends on its ability to expand within the Drug Manufacturers - Specialty & Generic sector while managing margin pressures.
- Future growth will depend on performance in core Drug Manufacturers - Specialty & Generic operations.
- The ability to manage competitive pressures will be crucial for sustained growth.
The primary risks for HIMS investors include debt exposure and competitive dynamics in the Drug Manufacturers - Specialty & Generic industry.
- $1.12B in debt could be a headwind in a high-rate environment.
- Fierce competition from established players in Drug Manufacturers - Specialty & Generic.
52-Week Trading Range
Over the past year, HIMS stock traded between $13.74 and $70.43—recovering meaningfully from lows and currently near the higher end. Big swings are likely unless a major catalyst emerges.
Volatility & Risk Profile
With 66.24% annualized volatility and β=2.61, the stock exhibits high sensitivity to market moves—making HIMS suitable for investors comfortable with active risk management.
Institutional & Insider Ownership
High institutional backing, but elevated short interest signals a potential battleground stock.
Analyst Sentiment & Price Targets
Latest News & Headlines
Recent headlines and coverage
Q4 Earnings Outperformers: Hims & Hers Health (NYSE:HIMS) And The Rest Of The Healthcare Technology Stocks
Wrapping up Q4 earnings, we look at the numbers and key takeaways for the healthcare technology stocks, including Hims & Hers Health (NYSE:HIMS) and its peers.
Stock Market Today, April 16: Hims & Hers Health Jumps on FDA Review of Compounded Peptide Therapies
On April 16, 2026, investors monitored an FDA peptide review that could be a boost to Hims & Hers Health.
Hims & Hers Spikes; Will The FDA Blow The Door Open On Peptide Compounding?
Hims stock jumped Thursday after the FDA said its advisors would weigh in on whether compounding pharmacies can make specific peptides.
These Stocks Are Today’s Movers: AMD, Intel, TSMC, Abbott, Hims, Corning, Schwab, Polaris, and More
Abbott Laboratories declines as first-quarter earnings highlight protracted challenges in its nutrition business.
Sector Update: Health Care Stocks Decline Late Afternoon
Health care stocks were softer late Thursday afternoon, with the NYSE Health Care Index and the Stat
What's Going On With Hims & Hers Stock Thursday
Regulatory Breakthrough Boosts Hims & Hers Stock Momentum
RFK Jr. Just Gave Hims & Hers Stock a Jolt. Should You Chase the Rally Here?
Hims & Hers stock rallies as RFK Jr. says FDA may remove restrictions on certain peptides. But HIMS shares remain unattractive to own in 2026.
Hims & Hers shares jump as FDA begins review of restricted peptide compounds
Shares of Hims & Hers Health (NYSE:HIMS) rose more than 8% to about $26 after the US Food and Drug Administration (FDA) moved to begin a formal review process that could eventually reshape the regulatory status of several wellness peptides used in compounding pharmacies. The FDA announced...
How RFK Jr. Sent Hims & Hers Stock Higher
Hims has signaled its interest in peptides, many of which have been banned for use in compounding pharmacies.
Hims & Hers stock extends gains as RFK Jr. signals FDA will consider looser restrictions on peptides
Hims & Hers stock jumped as RFK Jr. signaled that the FDA may ease restrictions on peptides.
Frequently Asked Questions
Common investor questions about Hims & Hers Health, Inc.
Hims & Hers Health, Inc. (HIMS) is currently trading at $26.99. The RSI (14-day) is at 58.3, indicating neutral territory. Wall Street analysts have a consensus "hold" recommendation. The mean analyst price target of $24.15 implies 10.5% downside from current levels. Volatility is high at 66.2% annualized, meaning significant price swings are common. Investors should consider their risk tolerance, investment horizon, and portfolio diversification before making a decision.
Based on current valuation metrics for Hims & Hers Health, Inc. (HIMS): The trailing P/E ratio is 37.53, which is above the market average, indicating investors are pricing in higher growth expectations. The forward P/E is 11.58, lower than the trailing P/E, suggesting analysts expect earnings improvement. The PEG ratio is 1.71, near 1.0, suggesting roughly fair value relative to growth. Price-to-Book is 8.04. Price-to-Sales is 1.86. Valuation should be compared to Drug Manufacturers - Specialty & Generic industry peers for context, as different sectors trade at different multiples.
Based on 13 analysts covering HIMS, the consensus price target is $24.15. This represents a 10.5% downside from the current price of $26.99. The range spans from a low target of $16.00 to a high target of $30.00, reflecting varying levels of optimism among analysts. The consensus recommendation is "hold". Note: Analyst price targets are forward-looking estimates and not guarantees of future performance.
Hims & Hers Health, Inc. (HIMS) does not currently pay a regular dividend. The company may be reinvesting profits into growth initiatives, or may not yet be profitable enough to distribute earnings to shareholders.
Key risks for Hims & Hers Health, Inc. (HIMS) investors include: 1. High volatility (66.2% annualized)—the stock can experience significant daily price swings. 2. Elevated debt levels (D/E ratio of 207.16) which could pressure margins in a rising rate environment. 3. Elevated short interest (45.2% of float) suggests significant bearish sentiment. 4. Broader market and macroeconomic risks (interest rates, inflation, geopolitical events). 5. Drug Manufacturers - Specialty & Generic sector-specific competitive pressures. Investors should diversify and consider their risk tolerance before investing.
Here is Hims & Hers Health, Inc.'s (HIMS) current debt and financial health profile: Total debt stands at $1.12B. The debt-to-equity ratio is 207.16, which is high and could pose financial risk if earnings decline or borrowing costs increase. The current ratio is 1.90, indicating strong short-term liquidity. The quick ratio is 1.51. The company holds $577.49M in cash and equivalents. Free cash flow is positive at $110.51M, providing a cushion for debt servicing and shareholder returns.